	US 12,243,623 B2
	Human therapeutic targets and modulators thereof
John Baxter Biggins, Long Beach, NY (US); Brian Roger Bowman, New Rochelle, NY (US); and Gregory L. Verdine, Boston, MA (US)
Assigned to LifeMine Therapeutics, Inc., Cambridge, MA (US)
Filed by LIFEMINE THERAPEUTICS, INC., Cambridge, MA (US)
Filed on Jul. 13, 2023, as Appl. No. 18/221,761.
Application 18/221,761 is a continuation of application No. 16/646,978, granted, now 11,749,375, previously published as PCT/US2018/051134, filed on Sep. 14, 2018.
Claims priority of provisional application 62/558,744, filed on Sep. 14, 2017.
Prior Publication US 2024/0212788 A1, Jun. 27, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. G16B 20/00 (2019.01); G16B 35/10 (2019.01)

CPC G16B 20/00 (2019.02) [G16B 35/10 (2019.02)]

19 Claims

1. A method comprising steps of:

a) querying a set of nucleic acid sequences, each of which is found in a fungal strain and comprises a biosynthetic gene cluster; and

b) identifying within at least one of the fungal nucleic acid sequences an embedded target gene (ETaG) sequence characterized in that it:

is not required for or is not involved in the biosynthesis of the product of the biosynthetic gene cluster;

is within a proximity zone relative to at least one gene in the cluster;

is homologous to a mammalian nucleic acid sequence; and

is optionally co-regulated with at least one biosynthetic gene in the cluster; and

c) assaying an effect of the product of the biosynthetic gene cluster, or an analog of the product, on a human target.